Chronic kidney disease, secondary to renal fibrogenesis, is a burden on public health. There is a need to explore new therapeutic pathways to reduce renal fibrogenesis. To study this, we used unilateral ureteral obstruction (UUO) in mice as an experimental model of renal fibrosis and microarray analysis to compare gene expression in fibrotic and normal kidneys. The cannabinoid receptor 1 (CB1) was among the most upregulated genes in mice, and the main endogenous CB1 ligand (2-arachidonoylglycerol) was significantly increased in the fibrotic kidney. Interestingly, CB1 expression was highly increased in kidney biopsies of patients with IgA nephropathy, diabetes, and acute interstitial nephritis. Both genetic and pharmacological knockout of CB1 induced a profound reduction in renal fibrosis during UUO. While CB2 is also involved in renal fibrogenesis, it did not potentiate the role of CB1. CB1 expression was significantly increased in myofibroblasts, the main effector cells in renal fibrogenesis, upon TGF-β1 stimulation. The decrease in renal fibrosis during CB1 blockade could be explained by a direct action on myofibroblasts. CB1 blockade reduced collagen expression in vitro. Rimonabant, a selective CB1 endocannabinoid receptor antagonist, modulated the macrophage infiltrate responsible for renal fibrosis in UUO through a decrease in monocyte chemoattractant protein-1 synthesis. Thus, CB1 has a major role in the activation of myofibroblasts and may be a new target for treating chronic kidney disease.
Kidney International advance online publication, 11 March 2015; doi:10.1038/ki.2015.63 KEYWORDS: cannabinoid; chronic kidney disease; fibrosis; myofibroblast Chronic kidney disease is a burden on public health systems, and it affects millions of individuals worldwide. Independently of its cause, chronic kidney disease is secondary to the replacement of functional renal tissue by extracellular matrix proteins (that is, fibrosis) that ultimately impair kidney function. Therefore, preventing renal fibrogenesis remains a major goal for clinicians. There are few new therapeutic options available, underscoring the urgent need to explore new potential therapeutic pathways to reduce renal fibrogenesis and chronic kidney disease.
To this end, we performed a microarray analysis that compared the gene expression profile of diseased and fibrotic versus normal kidneys in mice using the unilateral ureteral obstruction (UUO) experimental model. This model was thought best for this approach, as it is a rapid and reproducible model of renal fibrosis in mice, and it mimics the main steps of tubulointerstitial fibrosis in humans. 1 Unexpectedly, among the well-known pathways involved in renal fibrosis, expression of the Cnr1 gene (which encodes cannabinoid receptor 1 (CB1)) was found to be among the most significantly upregulated genes in the UUO model. The cannabinoid pathway acts through G protein-coupled cannabinoid receptors 1 (CB1) and 2 (CB2) that are best known for their roles in regulating food intake, body weight, thymic functions, and behavior. Therefore, the CB1 pathway is a major player in obesity and, more specifically, in metabolic syndrome and its related complications, such as atherosclerosis, 2 type 2 diabetes, and microalbuminuria. 3 However, CB1 seems to be also directly involved in both metabolic and nonmetabolic causes of liver. 4 In the kidney, CB1 expression is very low and is more prominently expressed in the vasculature where it regulates renal hemodynamics. 4 CB1 is involved in the development of microalbuminuria during diabetes and before overt nephropathy develops. 3, 5 This decrease in albuminuria in diabetic mice, obtained by blocking CB1, may be explained by changes in renal hemodynamics as glomeruli were normal under electron microscopy. 5 Recently, another study found a difference in mesangial expansion after CB1 blockade, with a decrease in profibrotic genes during the early stages of diabetic nephropathy in mice. 3, 5 So far, the role of CB1 in the development of overt nephropathy or in renal fibrogenesis has not been established.
Therefore, the objective of our study was to demonstrate that the cannabinoid receptors, and particularly CB1, represent an entirely new therapeutic pathway during renal fibrogenesis and act independently of their metabolic and renal hemodynamic effects.
RESULTS

CB1 expression is increased during the UUO model of renal fibrosis
We first compared the gene expression profile of three fibrotic kidneys with three undamaged contralateral kidneys in mice using the UUO model. We found many overexpressed genes in obstructed kidneys that are classically involved in renal fibrosis, such as Tgfb, Mmp, and Timp. However, using the DAVID (Database for Annotation, Visualization and Integrated Discovery) bioinformatics resources, the Cnr1 gene, encoding for CB1, was found to be one of the most upregulated genes in fibrotic kidneys, as illustrated by heatmaps that showed hierarchical clustering of significant transcripts ( Figure 1a ). This was confirmed using real-time quantitative PCR (RT-qPCR) (Figure 1b) .
Immunohistochemistry revealed that the CB1 receptor drastically increased during UUO and was expressed in the tubules, interstitium, and glomeruli. Indeed, no staining was found in the obstructed kidney of Cnr1 −/− mice, used as negative control (Figure 1c ). We performed double immunostainings in kidney cortex, using specific markers for T lymphocytes (CD3), macrophages (F4/80), and myofibroblasts (α-smooth muscle actin (α-SMA)). Under confocal microscopy, neither CD3 + lymphocytes nor F4/80 + macrophages expressed the CB1 receptor in obstructed kidneys. Nonetheless, we found coexpression of the CB1 receptor with the α-SMA marker in interstitial cells, indicating that CB1 was expressed in myofibroblasts in the kidney during UUO (Figure 2 ).
Endocannabinoid synthesis is altered during UUO
We quantified anandamide and 2-arachidonoylglycerol (2-AG), the main endogenous CB1 ligands within the kidney in mice during UUO. We found a significant increase of 2-AG (Po0.01), whereas anandamide decreased in UUO (Figure 1f ). However, 2-AG is 50-fold more abundant than anandamide in obstructed kidneys for a similar CB1 affinity (Supplementary Figure S1 online); therefore, we found a global increase in CB1 ligands during UUO. Using our microarray analysis, we also found that the transcription of genes involved in endocannabinoid synthesis was significantly altered during UUO (Supplementary Figure S2a-c online) .
CB1 expression is induced in human nephropathies
We next studied CB1 expression in normal and diseased kidneys in human renal biopsies. We found increased expression of CB1 in acute interstitial nephritis (n = 5), IgA nephropathy (n = 5), and diabetic nephropathy (n = 6) compared with a low level of CB1 expression in normal kidneys, mostly in endothelial cells (n = 5). In injured kidneys, CB1 expression was found in tubules, interstitial cells, and podocytes in diabetes nephropathy, and in mesangial cells in IgA nephropathy (Figure 3a-c) . In addition, CB1 expression correlates with kidney function (Po0.01) (Supplementary Figure S3 online ).
Both CB1 genetic invalidation and CB1 pharmacological blockade reduced fibrosis in the UUO model
We investigated the effect of CB1 deficiency on the development of renal fibrosis in the UUO model using genetic disruption of the CB1 gene (Cnr1) and specific pharmacological blockade of CB1. Histomorphometric analytical software was used to quantify renal fibrosis within an entire kidney cross-section with Sirius red (Figure 4a-c) .
After 8 days of UUO, as expected, we found a significant increase in collagen in obstructed compared with nonobstructed kidneys. The obstructed kidneys of Cnr1 −/− mice showed a 33% reduction in collagen accumulation compared with wild-type mice (Figure 4b) . Similarly, rimonabanttreated mice had a 65% reduction in fibrosis compared with vehicle-treated mice, using two different doses of rimonabant ( Figure 4d ). We also found a 25-60% reduction in fibrosis in AM6545 compared with vehicle-treated mice (Figure 4e) .
Our results were confirmed by quantification of collagen III by WB (Figure 4f ) and of collagen I and III mRNA using RT-qPCR (Figure 4g ).
CB2 is not involved in the CB1 blockade-dependent antifibrotic effect during UUO Because CB1 and CB2 may exert opposite physiological effects during liver fibrosis, 6 we investigated CB2 expression during UUO in CB1 blockade. We found a significant increase in Cnr2 (encoding the CB2 receptor) mRNA after UUO and during pharmacological and genetic CB1 blockade (Figure 5a ). This result was confirmed in immunohistochemistry (Supplementary Figure S4 online) .
To investigate whether the CB2 pathway was involved in the antifibrogenetic effect conferred by CB1 invalidation during UUO, we used a specific CB2 antagonist (SR144528) and an agonist (JWH133). Neither of these treatments further reduced the development of fibrosis when compared with the CB1 pharmacological blockade. However, the CB2 antagonist alone aggravated the development of fibrosis. In addition, the CB2 agonist alone blunted the development of fibrosis during UUO (Figure 5b ). markers reflect myofibroblast number in the cortex, although specific markers are lacking: indeed, these cells are highly plastic by nature. 7 Quantitative analysis showed that neither a specific α-SMA nor S100A4 immunostaining was significantly different during CB1 genetic disruption or CB1 pharmacological blockade (Figure 6a-d ). This suggests that the number of myofibroblasts that express these markers was not modified by the CB1 blockade.
Expression of TGF-β1 is not modified by a deficiency of CB1
Transforming growth factor-β1 (TGF) is indisputably one of the key drivers of fibrosis. We quantified TGF-β1 and TGFBI (transforming growth factor-β-induced) mRNA expression during UUO. TGFBI is a target gene of TGF-β1 and correlates with TGF-β1 activity in renal tissue. 8 We found their expressions to be significantly greater during UUO. However, this increase was not modified by genetic or pharmacological invalidation of CB1 (Figure 7a and b).
The role of the CB1 blockade in reducing renal fibrosis involves direct action on renal myofibroblasts
We next studied the role of CB1 in collagen synthesis using a primary cell culture of myofibroblasts in vitro. Indeed, we hypothesized that CB1 acts downstream of myofibroblast differentiation. We found weak basal myofibroblast expression of Cnr1 using RT-qPCR analysis and protein expression in western blotting. CB1 expression was notably increased after TGF-β1 treatment (Figure 8a and b). In addition, we found a significant amount of anandamide in culture supernatant that decreases after CB1 pharmacological blockade ( Figure 8c ). We found increased Col3a1 (encoding for Collagen III) expression after stimulation of myofibroblasts by TGF-β1 that was significantly blunted by rimonabant ( Figure 8d ). Similarly, Col3a1 expression remained low and stable upon TGF-β1 stimulation in Cnr1 − / − myofibroblasts ( Figure 8d ).
We also analyzed the effect of CB1 antagonism on monocyte chemoattractant protein-1 (MCP-1) synthesis, a major − / − mice and n = 6 for WT mice, n = 7 for all other groups). AU, arbitrary units. Bar scales = 100 μm.
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Kidney International b a s i c r e s e a r c h inflammatory cytokine chemoattractant for macrophages and produced by myofibroblasts, using enzyme-linked immunosorbant assay quantification. As expected, we found increased synthesis of MCP-1 after TGF-β1 stimulation that was significantly decreased after rimonabant treatment (Figure 8d) .
We also examined the role of CB1 in tubules during UUO. We found no major difference in tubular dilation during CB1 pharmacological blockade and a slight decrease in Crn1 − / − mice. Next, experiments carried out in HK-2 cells in vitro found that CB1 may not have a major role in collagen synthesis or in epithelial to mesenchymal transition (Supplementary Figure S6 online).
Macrophage infiltration during UUO is modulated by rimonabant but not by CB1 blockade
Inflammation is a key process during UUO and triggers the first steps of renal fibrogenesis. 9 Because we found decreased MCP-1 synthesis in rimonabant-treated myofibroblasts, we performed semiquantitative analysis on cells that had infiltrated the kidney cortex during UUO by immunostaining with T-lymphocyte (CD3) and macrophage (F4/80) markers (Figure 9a ). UUO significantly increased the staining of both CD3 and F4/80 in the kidney (data not shown). CB1 blockade had no effect on CD3-positive staining, whereas F4/80+ cell infiltration was significantly decreased during UUO.
We performed RT-qPCR analysis on selected M1-and M2-associated markers (Figure 9c-g ) in mRNA from the kidney cortex. Both M1 (iNOS, MCP-1, and IL-23) and M2 (Arg1 and Mrc1) markers were increased in obstructed kidneys. M1, but not M2, markers were reduced by rimonabant treatment during UUO compared with vehicletreated mice.
These results regarding macrophage infiltration during rimonabant treatment were not found in Cnr1 − / − mice or during CB1 blockage using AM6545. As expected, kidney cortex MCP-1 mRNA was not modified during UUO in both Cnr1
− / − and AM6545-treated mice (Supplementary Figure S5 online) . Thus, rimonabant may act on macrophages through noncanonical pathways.
DISCUSSION
Our study provides strong evidence, for the first time, for a major role of CB1 in the development of renal fibrosis: we have provided data from several human nephropathies, as well as from the UUO model in mice.
The fact that the expression of Cnr1 was found among the most upregulated genes in our microarray analysis during UUO was a first clue to its possible involvement in renal fibrogenesis. In addition, we found a very high increase in 2-AG, the most abundant CB1 ligand, during UUO. Moreover, CB1 expression is highly upregulated during UUO in the kidney tubules and podocytes, but also, more interestingly, in interstitial myofibroblasts. We found no expression of CB1 in immune-infiltrating cells in the kidney during UUO, in agreement with the literature on mice. 10 The prominent expression of CB1 in renal myofibroblasts strongly suggests a major role for the cannabinoid system in the development of renal fibrosis. We also found, for the first time, an important increase in CB1 expression in human nephropathies that seem to correlate with kidney function, whereas CB1 expression in normal kidneys was very low, as previously reported. 4 We have also demonstrated, for the first time, that both genetic invalidation of Cnr1 and CB1 pharmacological blockade drastically decreased the development of fibrosis in mice during UUO, proving the role of CB1 in the development of renal fibrosis. Moreover, genetic disruption and the CB1 pharmacological blockade were performed on two different genetic backgrounds, and this makes the role of CB1 in renal fibrogenesis even more relevant, as mice phenotypes are highly dependent on genetic background. 11, 12 We reproduced the reduction in renal fibrosis during UUO using both rimonabant and a peripherally restricted CB1 antagonist AM6545. This is an important result, as the use of rimonabant in humans is limited because of its adverse effects on the central nervous system (it was withdrawn from the market in 2008 (see Chorvat 13 ) despite its positive results on metabolic syndrome). Therefore, AM6545 could be used without the drawback of having adverse effects on the central nervous system. The proportional decrease in renal fibrosis during both genetic and pharmacological blockade of CB1 is extremely important, and it is comparable to that usually found during the blockade of the renin-angiotensin system during UUO. 14 This also suggests that CB1 may be a major pathway involved in fibrogenesis, as it is in other organs in metabolic 15 and nonmetabolic diseases, 14, 15, 16 although the complete UUO model may not completely be transferred into human pathology.
Because CB1 is mostly implicated in the regulation of food intake and glucose homeostasis, 17 targeting CB1 with a pharmacological blockade has been previously investigated in studies on diabetes and obesity. 2, 3 In addition to reducing body weight and metabolic parameters, the CB1 blockade decreases albuminuria during metabolic syndrome and during the early stages of diabetic nephropathies in mice and rats, 3,5 possibly through both hemodynamic effects and a direct action on the podocyte itself. 18 However, in diabetic mice, kidney lesions were absent 5 or faint. 18 Indeed, so far, none of the experimental models conducted on diabetic nephropathies in mice have been fully able to explore the overt renal fibrogenesis induced by diabetes in human diabetic kidneys. 11 Many reports suggest that CB2, which is mainly expressed in immune cells and less so in the central nervous system, may also be involved in the development of fibrosis. Contrary to CB1, CB2 disruption or pharmacological blockade has been reported to promote liver, cardiac, and skin fibrosis, whereas CB2 agonists decrease fibrogenesis, 6, 19, 20 Therefore, the blockade of renal fibrosis with CB1 invalidation during UUO may have been caused by the unbalanced actions of CB2; we also found increased expression of CB2. Interestingly, treatment with the CB2 agonist reduced fibrosis during UUO, whereas the CB2 antagonist aggravated renal lesions. In addition, the role of CB2 agonists in decreasing renal fibrosis has not been published (as yet), although the CB2 pathway has a role in decreasing albuminuria during diabetes. 21 We also found that the CB2 antagonist aggravates renal fibrosis during UUO. This result is in accordance with the − / − mice and n = 6 for WT mice, n = 7 for all other groups). KO, knockout. Bar scales = 100 μm.
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b a s i c r e s e a r c h work by Barutta et al., 22 who found direct participation of podocytes expressing CB2 during diabetic nephropathy in CB2 knockout mice. Moreover, renal fibrosis was reduced in a similar proportion during rimonabant treatment alone and during the association of rimonabant with a specific CB2 antagonist. Therefore, although the CB2 pathway alone seems to be involved in renal fibrosis, CB2 signaling is not necessary for mediating the antifibrotic effect of the CB1 pharmacological blockade. Similarly, adding a CB2 agonist during rimonabant treatment did not further decrease the development of renal fibrosis during UUO, and this rules out any additive or potentialization effect in the kidney, at least in our model. As our report provides solid evidence for the major implications of CB1 in renal fibrosis, we also attempted to decipher the exact mechanisms involved in reducing renal fibrosis. First, we explored the TGF-β1 pathway. TGF-β1 promotes myofibroblast activation or differentiation 7, 23 and is a major profibrotic cytokine in renal fibrosis, particularly in the UUO model. 24 We did not find any difference in TGF-β1 expression or in TGF-β1 target gene expression when CB1 was invalidated by either a pharmacological blockade or genetic disruption. This suggests that the activity of CB1 in our model took place downstream of TGF-β1, that is, on TGF-β1 target cells such as myofibroblasts.
Although its precise origin is still highly controversial, 21,24 the myofibroblast remains the main effector cell during renal fibrogenesis. During UUO in mice, we were able to demonstrate that cells expressing interstitial α-SMA, that is, myofibroblasts, also strongly expressed CB1. However, we were unable to demonstrate a decrease in cells that expressed α-SMA or S100A4 in the CB1 blockade during UUO. Myofibroblasts are highly plastic cells, and not all myofibroblasts express these markers, although they may still be involved in collagen synthesis. 8 Nevertheless, it is more likely that the CB1 blockade does not alter myofibroblast differentiation in vivo. We next used a primary cell culture of kidney myofibroblasts and found that rimonabant blunted the increased Col3 expression induced by TGF-β1. Similarly, we found no increase in collagen Col3 synthesis in Cnr1 − / − myofibroblasts upon TGF-β1 stimulation. Thus, CB1 is necessary for extracellular matrix protein synthesis in renal fibrosis, although its absence does not seem to alter myofibroblast differentiation in vivo. This result is expected given that undifferentiated myofibroblasts express very weakly, if not at all, the CB1 receptor. Although CB1 is expressed in tubules in UUO, it does not seem to have a major role in epithelial to mesenchymal transition in vitro.
Inflammation is a key mediator of renal fibrogenesis in the UUO model, and renal fibrosis can be blunted when macrophage and T-cell recruitment is reduced. 25, 26 It is still controversial whether there is significant CB1 expression in immune mouse cells, as some reports show weak 27 or no expression. 10 However, we found no significant expression of CB1 in CD3 lymphocytes or F4/80 macrophages during UUO. Nonetheless, there was a decrease in MCP-1 secretion by activated myofibroblasts in vitro during the CB1 blockade by rimonabant, and also a decreased number of M1-type macrophages during UUO, similar to that reported in the literature during atherosclerosis. 2 This could also account for the decreased fibrosis by rimonabant, as the role of M1-type macrophages promote renal fibrosis. 28 However, this is most likely a noncanonical effect of rimonabant as macrophage infiltration and MCP-1 transcription are not altered during AM6545 treatment or in Cnr1
− / − mice in kidney cortex in UUO. Therefore, the antifibrotic effect of rimonabant could also act through other receptors. Moreover, during CB1 blockade, endocannabinoids, which we found increased during UUO, could bind to receptors other than CB2, such as TRPV1. This hypothesis is in accordance with the work by Wang and Wang 29 who found that TRPV1 − / − mice have exaggerated renal damage in deoxycorticosterone acetate-salt hypertension. Overall, our work demonstrates that the main mechanism by which CB1 promoted renal fibrogenesis was its direct action on renal myofibroblast function. Thus, CB1 may be a major player in renal fibrosis, regardless of the initial renal injury: thus, it has promising therapeutic potential, as well as a good cardiovascular profile. − / − mice and n = 6 for WT mice, n = 7 for all other groups). 
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MATERIALS AND METHODS Microarray analyses
The hybridization procedure was performed according to the Agilent 60-mer oligo microarray processing protocol using an Agilent Gene Expression Hybridization Kit (Agilent Technologies, Santa Clara, CA). Agilent Feature Extraction Software was used to read out and process the microarray image files. Genes were considered to be differentially expressed if the Significance Microarray Analysis algorithm passed a false discovery rate of o0.01 and a fold change of 42. Functional analyses of the data were performed using the DAVID (The Database for Annotation, Visualization and Integrated Discovery) (v6.7) bioinformatics resource. Microarray data were deposited in GEO DataSets under accession number GSE38117. See Supplementary Materials and Methods online.
Drugs
Rimonabant was a gift from Sanofi-Aventis R&D (Montpellier, France) and AM6545 was purchased from Sigma-Aldrich (Saint Louis, MO).
JWH133 (Tocris Bioscience, Bristol, UK) and SR144528 (Cayman Chemicals, Ann Arbor, MI) were prepared in phosphate-buffered saline containing 10% dimethyl sulfoxide and 0.1% Tween-80. JWH133 and SR144528 were administered at doses of 1 mg/kg/day subcutaneously and 3 mg/kg/day intraperitonealy, respectively. All K i values are given in Supplementary Figure S1 online.
Animals
Mice, genetically invalidated for CB1 (Cnr1 −/− ) and wild-type mice (Cnr1 +/+ ) (CD1 background) were obtained from Dr C Ledent (Université Libre de Bruxelles, Brussels, Belgium) and generated as previously described 30 (also see Supplementary Materials and Methods online). All mice were housed under standardized conditions with a 12-h dark/light cycle, and unlimited access to food and water. All animal procedures were approved by the animal ethics advisory committee of Paris Sud University. 
Endocannabinoid quantification
Endocannabinoids were quantified in kidneys, brain, and myofibroblast culture supernatants with liquid chromatography coupled to Fourier transform mass spectrometry (see Supplementary Materials and Methods online).
Unilateral ureteral obstruction
After giving general anesthesia (isoflurane 2%), the left ureter was exposed via a mid-abdominal incision. UUO was performed with double silk sutures by complete ligation of the left ureter. The contralateral kidney served as an intraindividual control. Animals were killed on day 8 after treatment.
Histopathological analysis of renal fibrosis
Kidneys were fixed in 10% formalin and embedded in paraffin. Tissue sections (4 μm) were stained with Picrosirius red. Renal cortex fibrosis was quantified using computer-based morphogenic analysis software (TRIBVN CaloPix, Châtillon, France) in a blinded manner. The total kidney cortex of an entire kidney sagittal crosssection was selected for quantification from each mouse, representing ∼ 7 mm 2 surface area. The positive area was expressed as a percentage of the total cortical kidney section.
Immunohistochemistry
Paraffin-embedded kidney tissues were stained with an anti-α-SMA (Abcam, Cambridge), anti-CD3 (DakoCytomation, Glostrup, Denmark), anti-S100A4 (Abcam, Cambridge, UK), anti-F4/80 (Abcam), and anti-CB1 and CB2 (Abcam). Staining was quantified by a morphometry software.
Fluorescent immunostaining was revealed with anti-rabbit (Alexa Fluor 488, Jackson Immunoresearch, West Grove, PA) or anti-rat antibodies (DyLight 549, Jackson Immunoresearch). The slides were examined by confocal laser microscopy (Leica TCS SP5 AOBS Tandem Confocal System, Wetzler, Germany). See Supplementary Materials and Methods online.
Human kidney specimens Paraffin sections of renal biopsies from patients were retrospectively analyzed. Informed written consent was given by the patients for the use of part of the biopsy for scientific purposes. All procedures and the use of tissues were performed in accordance with the Declaration of Helsinki principles.
Real-time quantitative PCR (RT-qPCR) RNA was extracted from tissues or cells using a QIAGEN RNeasy Mini kit, according to the manufacturer's instructions (QIAGEN, Venlo, Netherlands). The cDNA was synthesized using a Revert Aid H minus First-Strand DNA Synthesis kit (Fermentas, Villebon-surYvette, France) and amplified by PCR with a LightCycler 480 (Roche Diagnostics, Meylan, France). See Supplementary Materials and Methods online and Table 1 for primers sequences.
Cell culture Primary cultures of mouse kidney myofibroblasts were isolated from C57/BL6 mice, as previously described. 31 See Supplementary Materials and Methods online. HK-2 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA). See Supplementary Materials and Methods online.
Enzyme-linked immunosorbant assay
The quantitative determination of mouse MCP-1 concentrations in primary myofibroblast supernatants was performed using a Quantikine enzyme-linked immunosorbant assay CCL2/MCP-1 kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Western blotting
Cells were lysed in NP-40 buffer containing protease inhibitors (Roche, Mannheim, Germany). Proteins, separated in a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, were transferred to a polyvinylidene fluoride membrane and then incubated with primary antibodies. See Supplementary Materials and Methods online.
Statistical analyses
We compared differences using the Mann-Whitney U-test or the paired Student's t-test, as appropriate. All analyses were performed using GraphPad Prism 5.0 software (La Jolla, CA). Data were considered statistically significant when the P-value was o0.05. All data are expressed as mean ± s.e.m.
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